Narcolepsy Therapeutics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

The Narcolepsy Therapeutics Market is segmented by Type (Cataplexy and Without Cataplexy), Product (Central Nervous System Stimulants, Sodium Oxybate, and Tricyclic Antidepressants), and Geography.

Narcolepsy Therapeutics Market Snapshot

Narcolepsy Therapeutics Market
Study Period: 2018 - 2026
Base Year: 2020
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 10.1 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The narcolepsy therapeutics market is anticipated to witness a CAGR of nearly 10.1% during the forecast period. The increasing prevalence of narcoleptic disorders across the world, rising stress levels, growing geriatric population, and increasing awareness about various treatment options for this condition are some of the factors expected to propel the market. As per the Narcolepsy Network, around 1 in every 2,000 people in the United States are affected by this condition.

The increase in awareness about the target disease among the general population and governments is expected to propel the narcolepsy therapeutics market. The rising number of people suffering from a host of narcoleptic disorders, including hallucinations, sleep paralysis, disrupted nocturnal sleep, and obesity, has caught the attention of governments around the world, forcing them to take necessary steps to address this condition. For instance, awareness campaigns are conducted by various networks, such as the National Center on Sleep Disorders Research, to address the needs of individuals with serious or mild narcoleptic conditions.

The approval and commercialization of new drugs by market players may also play a crucial role in driving the market growth over the coming years. For instance, in March 2019, Jazz Pharmaceuticals received the US FDA approval for Sunosi (solriamfetol), for the treatment of narcoleptic patients. However, delayed diagnosis or misdiagnosis may hamper the demand in the narcolepsy therapeutics market.

Scope of the Report

Narcolepsy is a long-term neurological disorder, which involves a decreased ability to regulate sleep-wake cycles. Symptoms include periods of excessive daytime sleepiness that last from seconds to minutes and can occur at any time. Around 70% of people experience episodes of a sudden loss of muscle strength, known as cataplexy, which can also strongly affect the emotional state of patients. The narcolepsy therapeutics market is segmented by type, product, and geography.

Type
Narcolepsy with Cataplexy
Narcolepsy without Cataplexy
Secondary Narcolepsy
Product
Central Nervous System Stimulants
Sodium Oxybate
Selective Serotonin Reuptake Inhibitors
Tricyclic Antidepressants
Other Products
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Narcolepsy with Cataplexy Dominates the Market

  • Narcolepsy with cataplexy is expected to dominate the global narcolepsy therapeutics market through the forecast period. This can be attributed to the rising prevalence of narcolepsy with cataplexy, which causes severe, irresistible daytime sleepiness and a sudden loss of muscle tone. As per the study of the National Sleep Foundation, almost 60-70% of narcoleptic patients suffer from narcolepsy with cataplexy.
  • The increasing awareness about the disease and the available treatment options leading to early diagnosis, as well as increasing healthcare expenditure, are the factors anticipated to drive this segment’s growth over the forecast period.
Narcolepsy Therapeutics Market

North America Represents the Largest Market and Asia-Pacific is Expected to Register the Fastest Growth

Currently, North America dominates the market studied, and it is expected to continue its stronghold for a few more years. The growing demand for sleep disorder treatment in the US and Canada, coupled with the increasing prevalence of narcoleptic disorders, increase in awareness, and high healthcare spending, is anticipated to drive the market. In addition, favorable reimbursement policies for therapeutic products, strong clinical pipeline, and rising stress levels are the other factors anticipated to promote revenue growth.

Asia-Pacific is anticipated to witness lucrative growth over the forecast period. Shift-work sleep disorder and increased stress levels are expected to expand the patient base in Asia-Pacific. These factors may contribute to the growing demand for drugs in these economies. Constantly improving healthcare reimbursement policies are expected to boost demand over the forecast period. In addition, increasing living standards have spurred regional demand. All these factors are anticipated to bode well for the regional market's growth in the forthcoming years.

Narcolepsy Therapeutics Market

Competitive Landscape

The major players include companies, such as Arena Pharmaceuticals Inc., BIOPROJET, Jazz Pharmaceuticals PLC, Ligand Pharmaceuticals Incorporated, Novartis, Shionogi Inc., Takeda Pharmaceutical Company Limited, and Teva Pharmaceuticals USA Inc.

Collaborations and acquisitions to share technology and costs for innovation in the field are expected to be observed. For instance, Takeda completed the acquisition of Shire in January 2019, overtaking the PROVIGIL product, which is a popular selling narcolepsy drug.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Global Prevalence of Narcolepsy

      2. 4.2.2 Narcolepsy Awareness Programs and Services

      3. 4.2.3 Presence of Reimbursement Policies Regarding Narcolepsy

    3. 4.3 Market Restraints

      1. 4.3.1 Adverse Effects and Risks Related to Narcolepsy Drugs

      2. 4.3.2 Delayed Diagnosis or Misdiagnosis

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 Type

      1. 5.1.1 Narcolepsy with Cataplexy

      2. 5.1.2 Narcolepsy without Cataplexy

      3. 5.1.3 Secondary Narcolepsy

    2. 5.2 Product

      1. 5.2.1 Central Nervous System Stimulants

      2. 5.2.2 Sodium Oxybate

      3. 5.2.3 Selective Serotonin Reuptake Inhibitors

      4. 5.2.4 Tricyclic Antidepressants

      5. 5.2.5 Other Products

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 United Kingdom

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle-East and Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle-East and Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Arena Pharmaceuticals Inc.

      2. 6.1.2 BIOPROJET

      3. 6.1.3 Jazz Pharmaceuticals PLC

      4. 6.1.4 Ligand Pharmaceuticals Incorporated

      5. 6.1.5 Novartis AG

      6. 6.1.6 Shionogi Inc.

      7. 6.1.7 Takeda Pharmaceutical Company

      8. 6.1.8 Teva Pharmaceuticals Industries Ltd

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Narcolepsy Therapeutics Market market is studied from 2018 - 2026.

The Narcolepsy Therapeutics Market is growing at a CAGR of 10.1% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2020.

Jazz Pharmaceuticals plc , Takeda Pharmaceutical Company , Teva Pharmaceuticals USA, Inc., Shionogi Inc, Novartis International AG are the major companies operating in Narcolepsy Therapeutics Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!